• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Atorvastatin Teva
    / Teva

    Active Ingredient
    Atorvastatin 10, 20, 40, 80 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 X 10 mg

    partial basket chart 29636 9520


    30 X 20 mg

    partial basket chart 29061 9523


    30 X 40 mg

    partial basket chart 29638 9521


    30 X 80 mg

    partial basket chart 18453 9384

    Related information


    See prescribing information for full details.


    Hypercholesterolemia: Adjunct to diet for the treatment of elevated total and LDL cholesterol, apolipoprotein B and triglycerides and to increase HDL-cholesterol in patients with primary hypercholesterolemia including familial hypercholesterolemia (heterozygous variant) or combined (mixed) hyperlipidemia (Fredrickson Types IIa and IIb) when response to diet and other non-pharmaceutical measures alone has been inadequate. To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments. Pediatric patients (10-17 years of age): As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains equal to or higher than 190 mg/dL, or b. LDL-C remains equal to or higher than 160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular disease: Prevention of cardiovascular and/or cerebrovascular events such as MI or stroke: As an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor.In patients with clinically evident coronary heart disease to reduce the risk of non-fatal myocardial infarction; to reduce the risk of fatal and non fatal stroke. To reduce the risk of hospitalization for CHF; to reduce the risk of angina.Reducing the risk for revascularization procedures.


    Known hypersensitivity to the active ingredient or to any other ingredient of the preparation. Patients with active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal. Patients with myopathy. Pregnancy and lactation. Women of child-bearing potential not using appropriate contraceptive measures. Should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards to the fetus. If the patient becomes pregnant while taking this drug, therapy should be discontinued and the patient apprised of the potential hazard to the fetus.

    Special Precautions

    Contact distributing company for full prescribing information.

    Side Effects

    Contact distributing company for full prescribing information.

    Drug interactions

    Erythromycin, digoxin, oral contraceptives, colestipol, warfarin, cyclosporine, itraconazole.
    See prescribing information for full details.

    Teva Pharmaceutical Industries Ltd, Israel